Literature DB >> 16199283

Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures.

Toshi Otsuka1, Hironori Kasai, Kazunori Yamaguchi, Tatsuji Nishihara.   

Abstract

OBJECTIVES: Enamel matrix derivative (EMD) is used clinically to promote periodontal tissue regeneration, however, there are few reports regarding effects of EMD on bone metabolism. We evaluated the influence of EMD on osteoclast formation using in vitro bone marrow culture.
METHODS: Bioactive fractions were purified from EMD by reverse-phase HPLC on a C18 hydrophobic support, then mouse bone marrow cells were cultured with EMD or its purified fractions for 8 days. Following tartrate resistant acid phosphatase (TRAP) staining, TRAP-positive multinucleated cells were counted. The expression of receptor activator of NF-kappaB ligand (RANKL) in osteoblastic cells was detected using immunoblotting.
RESULTS: EMD was dissolved in 0.1% (vol/vol) trifluoroacetic acid and applied to a C18 column for HPLC. Two major peaks were obtained of which the second (fraction numbers 21-25) was found to induce the formation of osteoclasts in mouse marrow cultures. Further, osteoprotegerin completely inhibited osteoclast formation in mouse marrow cultures with or without osteoblastic stromal cells, when being cultured with EMD or its purified fractions. In addition, Western blot analysis revealed the presence of RANKL in mouse osteoblastic cells stimulated with EMD or its purified fractions.
CONCLUSION: Our results indicate that EMD induces the formation of osteoclasts through RANKL expressed by osteoblastic cells, and suggest that EMD may regulate both bone formation and bone resorption during periodontal tissue regeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16199283     DOI: 10.1016/j.jdent.2005.02.006

Source DB:  PubMed          Journal:  J Dent        ISSN: 0300-5712            Impact factor:   4.379


  7 in total

1.  Ectopic study of tissue-engineered bone complex with enamel matrix proteins, bone marrow stromal cells in porous calcium phosphate cement scaffolds, in nude mice.

Authors:  X J Wang; H Huang; F Yang; L G Xia; W J Zhang; X Q Jiang; F Q Zhang
Journal:  Cell Prolif       Date:  2011-06       Impact factor: 6.831

2.  Cellular responses and expression profiling of human bone marrow stromal cells stimulated with enamel matrix proteins in vitro.

Authors:  Z C Song; R Shu; X L Zhang
Journal:  Cell Prolif       Date:  2009-11-17       Impact factor: 6.831

3.  TGF-βRI kinase activity mediates Emdogain-stimulated in vitro osteoclastogenesis.

Authors:  Reinhard Gruber; Gilles Roos; Jordi Caballé-Serrano; Rick Miron; Dieter D Bosshardt; Anton Sculean
Journal:  Clin Oral Investig       Date:  2013-11-13       Impact factor: 3.573

4.  A case report of dysosteosclerosis observed from the prenatal period.

Authors:  Kisho Kobayashi; Yusuke Goto; Hiroaki Kise; Hiroaki Kanai; Koji Kodera; Gen Nishimura; Kenji Ohyama; Kanji Sugita; Takayuki Komai
Journal:  Clin Pediatr Endocrinol       Date:  2010-08-31

5.  Effect of enamel matrix derivative on bone formation around intraosseous titanium implant: An experimental study in canine model.

Authors:  Reza Birang; Mohammad Shahabooei; Fatemeh Mashhadiabbas; Mehdi Atabaki; Narges Naghsh; Keikavous Kavosh; Ehsan Birang; Ahmad Mogharehabed
Journal:  Dent Res J (Isfahan)       Date:  2012-11

6.  Novel biological activity of ameloblastin in enamel matrix derivative.

Authors:  Sachiko Kuramitsu-Fujimoto; Wataru Ariyoshi; Noriko Saito; Toshinori Okinaga; Masaharu Kamo; Akira Ishisaki; Takashi Takata; Kazunori Yamaguchi; Tatsuji Nishihara
Journal:  J Appl Oral Sci       Date:  2015 Jan-Feb       Impact factor: 2.698

7.  Effect of Enamel Matrix Derivatives on Osteoclast Formation from PBMC of Periodontitis Patients and Healthy Individuals after Interaction with Activated Endothelial Cells.

Authors:  Gerlinde Durstberger; Phuong Quynh Nguyen; Verena Hohensinner; Peter Pietschmann; Xiaohui Rausch-Fan; Oleh Andrukhov
Journal:  Medicina (Kaunas)       Date:  2021-03-15       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.